To share pharmacoepidemiological learnings from own research.
8 scheduled presentations per year (posted here on DSFE’s homepage). Each session lasts 45 minutes and covers one specific paper and one theoretical topic. The theoretical presentation will constitute no more than 10 minutes and cover an issue related to the paper but presented in its own right, e.g. surveillance bias, propensity score adjustment, or reverse causation. The presentation of the paper focuses on the methods applied and the analytical choices made during the project (and their underlying rationale). The aim is to give a pragmatic walkthrough to highlight the practical issues faced, more so than the overarching methodology or clinical area of interest. The paper presentation takes no more than 25 minutes, which leaves 10 minutes for questions from attendees.
How to participate
We recommend testing the setup prior to the meeting by accessing the above link and clicking “Go to test site”.
All mics of participants will be muted centrally. In case of questions (during the last 10 minutes), please mark “raise your hand” and your mic will be centrally unmuted.
Last Friday of each month at 9.00 (only September-November and January-May)
|Date||Presenter||Paper||Theoretical topic||Link to previous presentations|
|Sep 28||Lina Steinrud Mørch||Association of Hormonal Contraception With Suicide Attempts and Suicides||Surveillance and healthy user bias||Presentation|
|Oct 26||Anton Pottegård||Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study.||Exposure ascertainment in cancer studies||Presentation|
|Jan 25||Ellen Løkkegaard||Using prescription registries to define continuous drug use: how to fill gaps between prescriptions.||Conditioning on the future in pharmacoepidemiology|
|Feb 28||Marie Hergrave||Maternal use of fertility drugs and risk of cancer in children—A nationwide population‐based cohort study in Denmark||Seperating effects of the treatment from the underlying disease|
|Mar 22||Kasper Adelborg||Use of histamine H2 receptor antagonists and outcomes in patients with heart failure: a nationwide population-based cohort study||New-user active comparator cohort studies|